When was Kaerus Bioscience founded?

Kaerus Bioscience was founded in 2017.

Where is Kaerus Bioscience located?

Kaerus Bioscience is headquartered in London, United Kingdom.

Who is the current CEO of Kaerus Bioscience?

Robert H Ring of Kaerus Bioscience.

How many employees does Kaerus Bioscience have?

As of Aug 31, 2026, the latest employee count at Kaerus Bioscience is 2.

Where does Kaerus Bioscience rank among its competitors?

Kaerus Bioscience ranks 1205th amongst 2973 active competitors, of which 1001 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kaerus Bioscience?

Kaerus Bioscience's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kaerus Bioscience - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of targeted therapeutics for rare neurodevelopmental disorders. It offer therapeutics that address an ion channel dysfunction in Fragile X syndrome that causes hyper-excitability of the central nervous system and targeting BK channels for rare genetic syndromes linked to the KCNMA1 gene.

Website: www.kaerusbio.com/
Social
Email ID: *****@kaerusbio.com

Key Metrics

Founded Year

2017

Location

London, United Kingdom

Stage

Funding Raised

Investors

Medicxi

Ranked

1205^th among 2973 active competitors

Employee Count

2 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 686 more

View Kaerus Bioscience's full profile

Kaerus Bioscience is a funded company. Kaerus Bioscience has 1 institutional investor.

View details of Kaerus Bioscience's funding rounds and investors

Kaerus Bioscience's employee count trend

Kaerus Bioscience has 2 employees as of Aug 26. Here is Kaerus Bioscience's employee count trend over the years:

Employee count trend for Kaerus Bioscience

Uncover Kaerus Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kaerus Bioscience include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Kaerus Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1205th	Kaerus Bioscience 2017, London (United Kingdom), Funding Raised	Developer of targeted therapeutics for rare neurodevelopmental disorders	-	Medicxi	36/100